Over the past decades, there have been great advances in the understanding of the
pathogenesis of venous thromboembolism (VTE) in patients with inherited and acquired …

Introduction Growing evidence supports the idea that microparticles (MPs) could contribute
to the pathogenesis of the thrombotic phenomena associated with antiphospholipid antibody …

Antiphospholipid syndrome is an autoimmune disease characterized by the persistent
presence of antiphospholipid antibodies, along with occurrence of vascular thrombosis and …

The antiphospholipid syndrome (APS) refers to persistent antiphospholipid antibodies (aPL)
associated with thrombotic and/or obstetrical complications. The endothelial cell is a target …

Microparticles (MP) are cell membrane derived fragments released as a result of apoptosis
or cellular activation that may be prothrombotic. Elevated numbers of microparticles may …

Microparticles (MPs) are irregularly shaped small vesicles of heterogeneous size released
from the plasma membrane in a tightly controlled process, after different stimuli. MPs have …

in microparticle production. Microparticles can influence the development of thrombosis in
many ways. For example, microparticles provide a catalytic surface for the assembly of …

Microparticles (MPs) are membrane-bound vesicles with important physiologic effects. MPs
exchange information intercellularly, with each kind of MP carrying antigens and receptors of …

Microparticles (MPs) are submicron vesicles released from the plasma membrane of
eukaryotic cells in response to activation or apoptosis. MPs are known to be involved in …

Antiphospholipid syndrome (APS) is a systemic autoimmune disease, characterized by
thrombosis, obstetric complications and the presence of antiphospholipid antibodies (aPL) …